mercredi 4 décembre 2019

Onco Actu du 4 décembre 2019


2. ETIOLOGIE



Philosophy of Biology: Characterizing causality in cancer [eLife]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy? [Fierce Pharma]











FDA ushers Merck's star cancer drug Keytruda toward another key checkpoint [EndPoints]










5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Struggling Adaptimmune gets a boost from the FDA as T cell cancer drug wins an inside track at the agency [EndPoints]











Antibody strategy to augment versatile immune cells sparks investment in French biotech [EndPoints]










5.12.6 IMMUNOTHÉRAPIES - AMM



FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer [Roche]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



One dose of radiotherapy as effective as five doses for cancer in the spine [University College London]










5.2 PHARMA



Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromes [Fierce Pharma]











5.2.6 PHARMA - BIOTECH



After FDA rejection, Immunomedics tries again with breast cancer drug [Biopharma Dive]











RAPT signs on with struggling Hanmi for Asian entrance of cancer therapy aimed at 'charged tumors' [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



F.D.A. Nominee Clears Senate Panel [NY Times]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Fostamatinib Received a Positive Opinion from the EMA for the Treatment of Primary Immune Thrombocytopenia [ESMO]











5.4 TRAITEMENTS - ECONOMIE



What Can the United States Learn from Pharmaceutical Spending Controls in France? [The Commonwealth Fund]










5.7.1 SABCS-COMMUNIQUÉS



Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium [Myriad]











6.1 OBSERVATION



A quarter of cancer patients experience avoidable delay to diagnosis [Cancer Research UK]










One in four cancer patients suffers delays being diagnosed, study finds [The Telegraph]











6.11 PATIENTS



As Use of Genomic Data Expands in Cancer Care, Patients Share Their Stories [NCI]










Expecting too much of “patient decision aids” [BMJ]










6.12 ETHIQUE



Cochrane announces a new, more rigorous “conflict of interest” policy [BMJ]











6.6 PUBLICATIONS



Publishers Announce a Major New Service to Plug Leakage [The Scholarly Kitchen]











6.7 DMP, BIG DATA & APPLIS



Patient data in the cloud [The Lancet Digital Health]











6.9 CONTROVERSES



Company Investigation Confirms No Asbestos in Johnson’s Baby Powder [Johnson & Johnson]











Johnson & Johnson says new tests show no asbestos in Johnson's Baby Powder [Reuters]